Systematic (IUPAC) name
Clinical data
Legal status
  • US: Not approved
CAS number  YesY
ATC code None
ChemSpider  N
Chemical data
Formula C16H20BrN 
Mol. mass 306.246 g/mol

Bromantane (brand name Ladasten) is a stimulant drug with anxiolytic properties developed in Russia during the late 1980s,[1][2] which acts mainly by inhibiting the reuptake of both dopamine and serotonin in the brain,[3][4][5][6] although it also has anticholinergic effects at very high doses.[7][8] It was used as a doping agent to enhance athletic performance, and several athletes tested positive for the drug at the 1996 Atlanta Olympic Games,[9] following which it was added to the banned list as a stimulant and masking agent. Research on this class of drugs has been fairly extensive and a large family of derivatives are known, although bromantane remains the best studied,[10] and human trials continue for applications such as increasing endurance under extreme conditions.[11]

Study results suggest that the combination of psychostimulant and anxiolytic actions in the spectrum of psychotropic activity of bromantane is effective in treating asthenic disorders compared to placebo. It is considered novel having both stimulant and anti-anxiety properties.[12]


  1. ^ Krapivin, SV; Sergeeva, SA; Morozov, IS (1993). "A quantitative pharmaco-electroencephalographic analysis of the action of bromantane". Biulleten' eksperimental'noi biologii i meditsiny 116 (11): 515–8.  
  2. ^ I.S. Morozov, I.A. Ivanova and T.A. Lukicheva (2001). "Search for New Drugs: Actoprotector and Adaptogen properties of Adamantane Derivatives (A Review)". Pharma. Chem. J. 35 (5): 235–238.  
  3. ^ Grekhova, TV; Gaĭnetdinov, RR; Sotnikova, TD; Krasnykh, LM; Kudrin, VS; Sergeeva, SA; Morozov, IS (1995). "The effect of bromantane, a new immunostimulant with psychostimulating action, on release and metabolism of dopamine in the dorsal striatum of freely moving rats: A microdialysis study". Biulleten' eksperimental'noi biologii i meditsiny 119 (3): 302–4.  
  4. ^ Kudrin, VS; Sergeeva, SA; Krasnykh, LM; Miroshnichenko, II; Grekhova, TV; Gaĭnetdinov, RR (1995). "The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain". Eksperimental'naia i klinicheskaia farmakologiia 58 (4): 8–11.  
  5. ^ Morozov, IS; Pukhova, GS; Avdulov, NA; Sergeeva, SA; Spasov, AA; Iezhitsa, IN (1999). "The mechanisms of the neurotropic action of bromantan". Eksperimental'naia i klinicheskaia farmakologiia 62 (1): 11–4.  
  6. ^ Seredenin, SB; Miramedova, AG (1999). "Analysis of pharmacological properties of bromantane". Biulleten' eksperimental'noi biologii i meditsiny 128 (11): 529–31.  
  7. ^ Bugaeva, LI; Verovskiĭ, VE; Iezhitsa, IN; Spasov, AA (2000). "An acute toxicity study of bromantane". Eksperimental'naia i klinicheskaia farmakologiia 63 (1): 57–61.  
  8. ^ Iezhitsa, IN; Spasov, AA; Bugaeva, LI; Morozov, IS (2002). "Toxic effect of single treatment with bromantane on neurological status of experimental animals". Bulletin of experimental biology and medicine 133 (4): 380–3.  
  9. ^ Burnat, P; Payen, A; Le Brumant-Payen, C; Hugon, M; Ceppa, F (1997). "Bromontan, a new doping agent". Lancet 350 (9082): 963–4.  
  10. ^ Morozov, IS; Klimova, NV; Sergeeva, SA; Ivanova, IA; Barchukov, VG; Kovalev, GI; Piatin, BM; Avdiunina, NI (1999). "Adamantane derivatives enhancing body's resistance to emergencies". Vestnik Rossiiskoi akademii meditsinskikh nauk / Rossiiskaia akademiia meditsinskikh nauk (3): 28–32.  
  11. ^ Viatleva, OA; Barchukov, VG; Morozov, IS; Salenko, IuA; Zhirnov, EN (2000). "The neuro- and psychophysiological effects of bromantane". Voenno-meditsinskii zhurnal 321 (8): 61–5, 96.  
  12. ^ Neznamov, GG; Siuniakov, SA; Teleshova, SE; Chumakov, DV; Reutova, MA; Siuniakov, TS; Mametova, LE; Dorofeeva, OA; Grishin, SA (2009). "Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov 109 (5): 20–6.